GC Biopharma "National Growth Fund Funding Approved... Accelerating 20% SCIG Development"
Aims to Submit a Phase 3 IND to the U.S. FDA Next Year
GC Biopharma said on November 3 that it had been selected as a company eligible for support from the National Growth Fund on October 29 and secured a total of KRW 170 billion to develop subcutaneous immunoglobulin (SCIG) for the U.S. market.
The National Growth Fund is a public-private financial program established to foster advanced strategic industries, including biotechnology, artificial intelligence (AI), semiconductors, and secondary batteries.
The company plans to use the funding for Phase 3 clinical trials of 20% SCIG and investment in production facilities, accelerating development. It aims to submit an investigational new drug (IND) application for a Phase 3 clinical trial to the U.S. Food and Drug Administration (FDA) in 2027.
In 2023, GC Biopharma became the first company in South Korea to receive FDA approval for a domestically developed immunoglobulin product, ALYGLO. It went on to achieve exports of more than $100 million in 2025. The company plans to launch new products through infrastructure investment and the rapid advancement of clinical trials, and quickly expand its market share alongside ALYGLO in the U.S. immunoglobulin market, valued at approximately KRW 20 trillion (about $14.4 billion).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
GC Biopharma CEO Huh Eun-cheol said, "With 20% SCIG joining ALYGLO, we will complete an immunoglobulin portfolio spanning both intravenous and subcutaneous injections."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.